Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 HKD | +2.56% | +3.45% | +14.29% |
03-26 | Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024 | CI |
03-25 | Dawnrays' 2023 Profit Falls 9% on Lower Revenue | MT |
Sales 2022 | 1.28B 176M 1.38B 241M | Sales 2023 | 1.15B 159M 1.24B 217M | Capitalization | 1.43B 198M 1.55B 270M |
---|---|---|---|---|---|
Net income 2022 | 358M 49.43M 387M 67.41M | Net income 2023 | 326M 45.01M 352M 61.38M | EV / Sales 2022 | 0.54 x |
Net cash position 2022 | 1.07B 148M 1.16B 202M | Net cash position 2023 | 1.05B 145M 1.14B 198M | EV / Sales 2023 | 0.33 x |
P/E ratio 2022 |
4.93
x | P/E ratio 2023 |
4.4
x | Employees | 1,143 |
Yield 2022 |
6.63% | Yield 2023 |
7.61% | Free-Float | 39.97% |
1 day | +2.56% | ||
1 week | +3.45% | ||
Current month | +2.56% | ||
1 month | +1.69% | ||
3 months | +9.09% | ||
6 months | +10.09% | ||
Current year | +14.29% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Xian Wu
CEO | Chief Executive Officer | 55 | 22-02-15 |
Yi jun Wu
DFI | Director of Finance/CFO | 59 | 02-11-30 |
Kei Ling Li
CHM | Chairman | 75 | 02-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kei Ling Li
CHM | Chairman | 75 | 02-09-30 |
Yung Lai Hung
BRD | Director/Board Member | 79 | 02-09-30 |
Hong Man Leung
BRD | Director/Board Member | 49 | 05-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-28 | 1.2 | +2.56% | 60 000 |
24-04-26 | 1.17 | 0.00% | 40,000 |
24-04-25 | 1.17 | 0.00% | 0 |
24-04-24 | 1.17 | -1.68% | 144,000 |
24-04-23 | 1.19 | +2.59% | 112,000 |
Delayed Quote Hong Kong S.E., April 28, 2024 at 11:11 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+14.29% | 224M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 2348 Stock